Researchers at the Lks Faculty of the University of Hong Kong (HKUMED) Have Invented An Oral Formulation of Arsenic Trioxide (Oral -TO; Arsenol) for the treatment of acute prady Ood cancer that Once a high Fatality rate.

The invention and use of oral-to is of history important for medicine in hong kong. It is the first-ever prescription medicine invented and manufactured in hong kong, and also the first to obtain us, European and Japanese Patents.

After more than two decades of dedicated work, the HKU research team successfully translated this Hong Kong invention into clinical practice by incorporating oral-ATO into the treatment plan of APL patients. Extensive Clinical Studies Of Oral-Ato Demonstrated Its High Efficiency and Safety in Curing APL Patients, with An Overall Survival (OS) Rate Excasing 97%, Along with a Significant in SIDE-EFFECTS and Treatment Burdeen.

Excellent Results of Oral -TO for APL

For more than two decades, the hkumed research team performed extended extended extended Studies on Oral -TO for APL. In A 15-YAR Prospective Follow-Up Study of More Than 400 Patients with Relapsed APL, Oral -TO-Based Treatment Resulted in A 100% Molecular Remision Rate and A Five-Year OS Rate of 80%. These outcomes were achieved without bone marrow transplantation, a highly toxic treatment that is still used in many parts of the world that that do not have access to oral-current.

The hkumed research team then moved oral-to to the maintenance treatment of APL Patients in First Complete Remission, Resulting in A 90% Five-Yaar Leukemia-Free Survival (LFS) Rate and A 97% OS Rate. The Next Step was the Incorporation of Oral -TO Frontline Treatment of Newly Diagnosed APL Patients, Achieving 100% LFS and OS at Five Years.

Following these studies, the hkumed research team developed a treatment plan Compirising Timely Treatment Initiation, Necessary Supportive Care and the frontline use of oral-to. This approach has been reduced the incident of early deaths related to apl complications, which in the past a fatality rate of up to 20%-30%.

The hkumed research team is currently tested frontline treatment in hong kong with an entryly oral regimen comparising oral-to, all-trans retinoic acid (atra) and aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa Anner.

Oral-to as the new standard of care in apl

According to Dr. Harinder Gill, Clinical Associate Professor in the Department of Medicine, School of Clinical Medicine of Hkume, The Study’s Lead Investigator, The Entrely Oral Regimeen “Aaa” ministed in an outpatent setting for all risk categories of apl Patients. It can minimize chemotherapy in patients at all risk levels-not just in lower-risk patients –is well as in both children and adults.

Recognition by the US FDA and the Ema

As part of the first steps in Placing Oral -TO in the International Arena of Medicine, Oral -TO Obtaned orphan Drug Designation (ODD) from the Us FOOOOD and Drug Administation (FDA) as well as An Investigational New Drug Designation (IND) From the US FDA. Oral-to is the first prescription anti-country drug inverted in hong kong to obtain key fda and ema designs, which are Pivotal Requisites for Global Studies of Oral -TO.

The APL Asian Consortium, LED by Hkume, Bringther Researchers from Hong Kong, Malaysia, Singapore and Taiwan to Focus on APL Research and Treatment. Their first retrospective analysis demonstrated the superiority of the frontline “aaa” regimeen to more conventional regimens that include chemotherapy. The apl asian consortium is currently a platform for promoting the use of oral-to in these regions.

Globalization of Oral -TO

Greater Bay Area (GBA) and Asia

The Hkumes Researchers Teamed Up With Researchers in the GBA (Through HKU-Shenzhen Hospital) and Asia (via National University Cancer Institute Singapore and National University University, Singapore, Singapore) Ato. This multicenter research team demonstrated a three-yar os and relapes-free survival (RFS) Rate of 99% and 97%, Respectively.

Oral-to has been approved by the Guangdong Provincial Medical Products Administration (GDPA) for Clinical Use in the GBA Via the HKU-Shenzhen Hospital. Under the aegis of the asian APL Consortium, Oral -TO is available for research and clinical use on APL Patients in Singapore, Malaysia and Taiwan.

United Kingdom

The UK Aml Research Network and the University of Cardiff, UK, in Collaboration with the Hkumes Research Team, Obtained Funding from Blood Cancer UK for Oral -TO. A nation-wide phase 3 study incorporating oral-to will be investment in the frontline management of apl in the uk. This is a landmark for medicine development in hong kong.

Us and europe

Odds granted by the US FDA and the ema provide the regulatory requirements for study of oral-to in the us and europe. The hkumed results will team up with industry partners to conduct these clinical studies, which are set to commence in hong kong, North America and Europe this year.

Apl as a due disease

“We take great pride in seeing our research translated into practice in hong kong and around the world,” said Dr. Gill. “The development of oral-to is a game-Congress for APL Patients. It offers a convenient and effective treatment option that can significantly improvement of life.

“We are proud to play a pioneering role in bringing this innovation to the world and are committed to ensuring that all APL patients have access to this life-saving and cost-effective therapy. In this way, we aim to make APL a curable disease For Patients Around the World.